J&J Pushes Back Launch Of Ottava Robotic Platform By Two Years
The company originally expected the first-in-human trial of the soft-tissue robotic surgery system to begin in late 2022 and reach the market by 2023, but the company now expects those trials to begin in 2024.
You may also be interested in...
J&J originally projected its Ottava soft-tissue robotic surgery system would enter first-in-human trials in 2022 and reach the market by 2023, but the development has been delayed by technical challenges and COVID-19-related disruptions. Now the company plans to start trials of a four-armed version of the device in about a year.
This week, we learned that the US FDA thinks Elon Musk’s Neuralink brain interface device isn’t ready for human trials. Additionally, J&J cut about 300 medtech jobs, Stryker launched a knee implant, and Active Implants’ meniscus replacement device made it to the FDA’s advisory panel calendar.
Johnson & Johnson plans to buy Abiomed for $380 per share – about $16.6bn in total – plus up to $35 per share in potential commercial and clinical milestone-contingent payments. Abiomed is the clear leader in percutaneous circulatory support technology, but would benefit from J&J's reach and resources while complementing J&J's Biosense Webster electrophysiology business.